The real world study included more than 1 million people ages 60 or older who received a third dose of Pfizer’s COVID-19 at least five months after their second dose. The study took place in Israel, which approved COVID-19 boosters this summer.
The study also found that booster doses lowered the risk of severe disease more than 10-fold. The researchers noted that this figure, as well as the 11-fold decrease in infection risk, is an estimate.
The research is preliminary, and its findings still need to be confirmed with further investigation. One of the study’s limitations is that the people who received Israel’s first booster shots may have been more risk-averse than the general population.
U.S. officials have been examining the data presented in the study to help inform decisions on Americans’ booster timeline, according to The Wall Street Journal.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
